Skip to main content

Advertisement

Log in

Gastrointestinal infections caused by cytomegalovirus

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Cytomegalovirus (CMV) is an important human pathogen, causing a variety of syndromes ranging from asymptomatic infections to life-threatening end-organ disease. Infections of the gastrointestinal tract are an especially common form of disease caused by CMV and are usually manifest as luminal infections, such as esophagitis or colitis. Solid organ disease caused by CMV is also known to occur, with hepatitis being the most common syndrome. The large majority of cases of tissue-invasive disease caused by CMV have been reported to occur in immunocompromised hosts. Patients at highest risk for serious CMV-mediated disease are commonly HIV infected, recipients of transplants, or are receiving potent immunosuppressive medications. Intriguingly, several recent reports have discussed the previously underappreciated role of serious forms of CMV-mediated disease occurring in immunocompetent patients. This paper reviews several recent reports addressing important aspects related to the diagnosis, treatment, and management of CMV infections of the gastrointestinal tract.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Pass RF: Cytomegalovirus. Pediatr Rev 2002, 23:163–170. Excellent overview of CMV.

    PubMed  Google Scholar 

  2. Sissons JGP, Carmichael AJ: Clinical aspects and management of cytomegalovirus infection. J Infection 2002, 44:78–83. Review of current management aspects of CMV infection, including infection of normal hosts.

    Article  CAS  Google Scholar 

  3. Pass RF: Cytomegalovirus. In Fields Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2001:2675–2706.

    Google Scholar 

  4. Mocarski ES, Courcelle CT: Cytomegaloviruses and their replication. In Fields Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2001:2629–2674.

    Google Scholar 

  5. Mocarski ES: Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002, 10:332–339. Review of mechanisms of CMV immune evasion.

    Article  PubMed  CAS  Google Scholar 

  6. Beisser PS, Goh CS, Cohen FE, Michelson S: Viral chemokine receptors and chemokines in human cytomegalovirus trafficking and interaction with the immune system. CMV chemokine receptors. Curr Top Microbiol Immunol 2002, 269:203–234.

    PubMed  CAS  Google Scholar 

  7. Miller DM, Cebulla CM, Sedmark DD: Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction. Curr Top Microbiol Immunol 2002, 269:153–170.

    PubMed  CAS  Google Scholar 

  8. Grangeot-Keros L, Cointe D: Diagnosis and prognostic markers of HCMV infection. J Clin Virol 2001, 21:213–221. Summarizes the currently available assays for the diagnosis and management of CMV infection.

    Article  PubMed  CAS  Google Scholar 

  9. Razonable RR, Rivero A, Rodriguez A, et al.: Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002, 40:746–752.

    Article  PubMed  Google Scholar 

  10. Singh N: Cytomegalovirus infection of liver transplant recipients: comparison of antigenemia and molecular biology assays. Liver Transplant 2001, 7:1004–1007.

    Article  CAS  Google Scholar 

  11. Zaia J: Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002, 35:999–1004. Review of anti-CMV strategies for use in stem cell transplant recipients.

    Article  PubMed  Google Scholar 

  12. Humar A, Kumar D, Bolvin G, Calliendo AM: Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002,186:829–833.

    Article  PubMed  Google Scholar 

  13. Rayes N, Seehofer D, Schmidt CA, et al.: Is preemptive therapy for CMV infection following liver transplantation superior to symptom-triggered treatment? Transplant Proc 2001; 33:1804.

    Article  PubMed  CAS  Google Scholar 

  14. Koetz AC, Delbruck R, Furtwangler A, et al.: Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001, 72:1325–1327.

    Article  PubMed  CAS  Google Scholar 

  15. Singh, N: Preemptive therapy for cytomegalovirus with oral ganciclovir after liver transplantation. Transplantation 2002, 73:1977–1978.

    Article  PubMed  Google Scholar 

  16. Paya C, Wilson J, Espy M, et al.: Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002, 185:854–860.

    Article  PubMed  CAS  Google Scholar 

  17. McGavin JK, Goa KL: Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61:1153–1183. Comprehensive review of ganciclovir use: indications, pharmocokinetics, and adverse effects.

    Article  PubMed  CAS  Google Scholar 

  18. Drew WL, Paya CV, Emery V: Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 2001, 1:307–312.

    Article  PubMed  CAS  Google Scholar 

  19. Emery VC: Progress in understanding cytomegalovirus drug resistance. J Clin Virol 2001, 21:223–228.

    Article  PubMed  CAS  Google Scholar 

  20. Limaye A: Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002, 35:866–872. Detailed, current review of the mechanisms, pathogenesis, and managmenent of ganciclovir-resistant CMV.

    Article  PubMed  CAS  Google Scholar 

  21. Lurain N, Bhorade M, Pursell K, et al.: Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002,186:760–768.

    Article  PubMed  CAS  Google Scholar 

  22. Griffiths PD: Cytomegalovirus therapy: current constraints and future opportunities. Curr Opin Infect Dis 2001, 14:765–768.

    PubMed  CAS  Google Scholar 

  23. Khare MD, Sharland M: Cytomegalovirus treatment options in immunocompromised patients. Expert Opin Pharmacother 2001, 2:1247–1257.

    Article  PubMed  CAS  Google Scholar 

  24. Curran M, Noble S: Valganciclovir. Drugs 2001, 61:1145–1150.

    Article  PubMed  CAS  Google Scholar 

  25. Segarra-Newnham M, Salazar MI: Valganciclovir: a new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals. Pharmacotherapy 2002, 22:1124–1128.

    Article  PubMed  CAS  Google Scholar 

  26. van der BijW, Speich R: Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001, 33(Suppl 1):S32-S37.

    PubMed  Google Scholar 

  27. Morales E, Andres A, Gonzalez E, et al.: Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy. Transplant Proc 2002, 34:73–74.

    Article  PubMed  CAS  Google Scholar 

  28. Martinez A, Castro A, Gil C, Perez C: Recent strategies in the development of new human cytomegalovirus inhibitors. Med Res Rev 2001, 21:227–244.

    Article  PubMed  CAS  Google Scholar 

  29. Emery VC, Hassan-Walker AF: Focus on new drugs in development against human cytomegalovirus. Drugs 2002, 62:1853–1858. Highlights of current directions in antiviral agents for CMV.

    Article  PubMed  CAS  Google Scholar 

  30. Temperton NJ: DNA vaccines against cytomegalovirus: current progress. Int J Antimicrobial Agents 2002, 19:169–172.

    Article  CAS  Google Scholar 

  31. Karakozis S, Gongor E, Caceres M, et al.: Life-threatening cytomegalovirus colitis in the immunocompetent patient: report of a case and review of the literature. Dis Colon Rectum 2001, 44:1716–1720. Overview of case reports related to CMV colitis in immunocompetent individuals.

    Article  PubMed  CAS  Google Scholar 

  32. Ng FH, Chau TN, Cheung TC, et al.: Cytomeglovirus colitis in individuals without apparent cause of immunodeficiency. Dig Dis Sci 1999, 44:945–952. Description of several cases of CMV colitis in immunocompetent individuals.

    Article  PubMed  CAS  Google Scholar 

  33. Gill AJ, Eckstein RE: Cytomegalovirus mimicking fulminant colitis in a patient with chronic ulcerative colitis-a case report and review of the incidence in 14 patients with the clinical syndrome of fulminant colitis. Pathol Int 2001, 51:A4.

    Google Scholar 

  34. Bloomfeld RS: Are we missing CMV infections in patients hospitalized with severe colitis? Inflamm Bowel Dis 2001, 7:348–349.

    Article  PubMed  CAS  Google Scholar 

  35. Olofinlade O, Chiang C: Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol 2001, 32:82–84.

    Article  PubMed  CAS  Google Scholar 

  36. Battaglino MP, Rockey DC: Cytomegalovirus colitis presenting with the endoscopic appearance of pseudomembranous colitis. Am Soc Gastrointest Endosc 1999, 50:697.

    Article  CAS  Google Scholar 

  37. Page M, Dreese J, Poritz L, Koltun W: Cytomegalovirus enteritis: a highly lethal condition requiring early detection and intervention. Dis Colon Rectum 1998, 41:619–623.

    Article  PubMed  CAS  Google Scholar 

  38. Vega R, Bertran X, Menacho E, et al.: Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 1999, 94:1053–1056.

    Article  PubMed  CAS  Google Scholar 

  39. Cottone M, Pietrosi G, Martorana A, et al.: Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am J Gastroenterol 2001, 96:773–775.

    Article  PubMed  CAS  Google Scholar 

  40. Kaufman H, Kahn A, Jacobuzio-Donahue C, et al.: Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum 1999, 42:24–30.

    Article  PubMed  CAS  Google Scholar 

  41. Pfau P, Kochman M, Furth E, et al.: Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naïve patient. Am J Gastroenterol 2001, 96:895–899.

    Article  PubMed  CAS  Google Scholar 

  42. Papadakis K, Tung J, Binder S, et al.: Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:2137–2142.

    Article  PubMed  CAS  Google Scholar 

  43. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094–1097. Important monograph proposing standardized definitions for various forms of CMV infection and disease.

    Article  PubMed  Google Scholar 

  44. Castiglione F, Del Vecchio Blanco G, Rispo A, et al.: Hepatitis related to cytomegalovirus infection in two patients with Crohn’s disease treated with azathioprine. Dig Liver Dis 2000, 32:626–629.

    Article  PubMed  CAS  Google Scholar 

  45. Chan A, Dieckhaus KD, Ramsey W: Cytomegalovirus hepatitis in a nontransplant patient with autoimmune hepatitis taking immunosuppressants. Am J Gastroenterol 2001, 96:262–263.

    Article  PubMed  CAS  Google Scholar 

  46. Ohkuchi A, Minakami H, Suzuki I, et al.: Liver dysfunction in late pregnancy: cytomegalovirus-induced hepatitis or the HELLP syndrome? J Obstet Gynaecol Res 2001, 27:319–323.

    Article  PubMed  CAS  Google Scholar 

  47. Revello MG, Gerna G: Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002, 15:680–715.

    Article  PubMed  Google Scholar 

  48. Funato T, Satou N, Abukawa D, et al.: Quantitative evaluation of cytomegalovirus DNA in infantile hepatitis. J Viral Hepatitis 2001, 8:217–222.

    Article  CAS  Google Scholar 

  49. Tajiri H, Kozaiwa K, Tanaka-Taya K, et al.: Cytomegalovirus hepatitis confirmed by in situ hybridization in 3 immunocompetent infants. Scand J Infect Dis 2001, 33:790–793.

    Article  PubMed  CAS  Google Scholar 

  50. Varani S, Lazzarotto T, Margotti M, et al.: Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. J Med Virol 2000, 62:25–28.

    Article  PubMed  CAS  Google Scholar 

  51. Teixeira R, Pastacaldi S, Davies S, et al.: The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000, 70:1454–1458. Reports an adverse association between the reactivation of CMV infection and course of HCV in liver transplant recipients.

    Article  PubMed  CAS  Google Scholar 

  52. Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplant 2002, 8:362–369.

    Article  Google Scholar 

  53. Razonable RR, Burak K, van CruijsenH, et al.: The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002, 35:974–981. Confirms and extends the negative effects of CMV infection in HCVinfected liver transplant recipients.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bobak, D.A. Gastrointestinal infections caused by cytomegalovirus. Curr Infect Dis Rep 5, 101–107 (2003). https://doi.org/10.1007/s11908-003-0044-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-003-0044-4

Keywords

Navigation